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hristchurch and Auckland, New Zealand; and Sydney, Australia
OBJECTIVES The aim of this work was to test B-type natriuretic peptides for assessment of function and
prognosis in stable ischemic heart disease (IHD) and to compare brain natriuretic peptide
(BNP) with amino terminal pro-brain natriuretic peptide (NTproBNP), including the
relative effects of age and renal function on test performance.
BACKGROUND Brain natriuretic peptide and NTproBNP are emerging diagnostic and prognostic markers in
heart failure and acute coronary syndromes. Their performance in assessing function and
prognosis in stable IHD is unknown. Whether one marker is superior and the relative effects
of age and renal function on test performance are uncertain.
METHODS In 1,049 patients with stable IHD, left ventricular ejection fraction (LVEF) was measured by
radionuclide scanning and creatinine clearance estimated by the Cockroft-Gault equation.
Age, gender, and body mass index were recorded. Twelve-month all-cause mortality or
admission with heart failure was prospectively recorded; BNP and NTproBNP were
measured by radioimmunoassay.
RESULTS Brain natriuretic peptide and NTproBNP correlated closely (r  0.90, p  0.001) and had
similar relationships to LVEF (r0.50 and0.46, respectively, both p 0.001), age (0.44
and 0.47, both p  0.001), and creatinine clearance (0.51 and 0.51, both p  0.001).
Areas under receiver-operating characteristic curves for detection of LVEF 30% were
similar (0.83 and 0.80, both p  0.001) with strong negative predictive values for both (95%
and 94%). Both markers independently predicted the clinical end point with closely
overlapping event-free survival curves.
CONCLUSIONS In stable IHD, BNP and NTproBNP display strong and near-identical test performance in
ruling out severely reduced LVEF and in prediction of all-cause mortality or heart failure
despite significant effects of age, gender, and renal function on levels of both markers. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.085Coll Cardiol 2006;47:52–60) © 2006 by the American College of Cardiology Foundation
p
h
t
(
f
c
a
s
o
c
t
a
(
N
l
e
t
rhe B-type natriuretic peptides (i.e., brain natriuretic pep-
ide [BNP] and amino terminal pro-brain natriuretic pep-
ide [NTproBNP]) are acknowledged biomarkers of cardiac
unction and prognosis. Clinical applications under ongoing
See page 61
nvestigation include their use as a diagnostic test for the
resence of heart failure in the newly symptomatic (most
ommonly dyspneic) patient (1–5); risk stratification for
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Manuscript received January 19, 2005; revised manuscript received April 28, 2005,
ccepted June 13, 2005.rognosis after recent cardiac decompensation, in chronic
eart failure, or after acute coronary events (6–17); moni-
oring and adjustment of therapy in chronic heart failure
18,19); and screening of asymptomatic at-risk populations
or significant cardiac impairment (20–25). Studies in
ardiovascular patients have been confined to those with
cute heart failure, chronic heart failure, and acute coronary
yndromes (1–17). There is little information on the utility
f B-type natriuretic peptides across the spectrum of stable
hronic ischemic heart disease (IHD), although such pa-
ients generate a large proportion of cardiological practice.
Whether BNP or NTproBNP measurements offer any
dvantage over the other in any clinical setting is controversial
26–32). Initial reports from Hunt et al. (26,27) demonstrating
TproBNP was present in human plasma (with increased
evels in heart failure) also suggested NTproBNP may detect
arlier, asymptomatic cardiac impairment with greater sensi-
ivity than BNP (27). Some subsequent reports have corrobo-
ated this suggestion (28–30), although counterclaims have
lso been made (31,32). Notably, in several reports the pur-
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January 3, 2006:52–60 B-Type Natriuretic Peptides in Stable IHDorted differences in test performance have not attained statis-
ical significance (29–31).
Gender, age, renal function, and body mass index (BMI) all
nfluence plasma B-type natriuretic peptide levels (13,15,21,
5,33,34). In severe, recent-onset symptomatic heart failure,
lasma BNP is typically elevated many times above normal,
nd the influence of acute heart failure on BNP generally far
utweighs that of these other factors, which do not alter
eptide levels sufficiently to substantially abrogate the diagnos-
ic utility of BNP in distinguishing dyspnea due to acute heart
ailure from that due to other causes (1–5,33). However, in
table IHD less profound elevation of BNP or NTproBNP
ay be anticipated, and the potential employment of peptide
evels to reflect cardiac function and to assist in risk stratifica-
ion of stable patients may be more vulnerable to confounding
y these factors. Some authors also assert that age and renal
unction have a greater effect on levels of one peptide marker
implying a more potentially confounding influence on test
erformance) than the other (32). However, consensus on such
uestions has yet to be reached.
This report provides a comparison of BNP with NT-
roBNP and assesses their performance in over 1,000
atients with stable IHD. The ability of both peptides to
etect left ventricular ejection fraction (LVEF) reduced
elow pre-set thresholds is tested in both symptomatic and
symptomatic patients, and the relative effects of age,
ender, and renal function and BMI on plasma peptide
evels are also assessed. Finally, we compare the prognostic
erformance of both peptides in predicting death and/or
dmission with decompensated heart failure over 12
onths’ follow-up.
ETHODS
tudy population. Patients were included from both the
ustralia-New Zealand (ANZ) Heart Failure trial (8,9,35)
nd the Christchurch Cardioendocrine post-myocardial in-
arction (PMI) cohort (11,36).
The ANZ heart failure patients (n  292) participated in a
andomized trial of carvedilol with results as previously pub-
ished. Recruited from 20 hospitals in ANZ, they had chronic
table IHD (defined as a documented history of myocardial
Abbreviations and Acronyms
ANZ  Australia-New Zealand
AUC  area under the curve
BMI  body mass index
BNP  brain natriuretic peptide
IHD  ischemic heart disease
LVEF  left ventricular ejection fraction
NTproBNP  amino terminal pro-brain natriuretic
peptide
NYHA  New York Heart Association
PMI  post-myocardial infarction
ROC  receiver-operating characteristicnfarction, typical angina, exercise test positive for ischemia, or ingiographic evidence of coronary disease) and LVEF by
adionuclide ventriculography of 45%. At recruitment they
ere of New York Heart Association (NYHA) functional class
I or III. Exclusion criteria included coronary events or proce-
ures within the previous four weeks and primary myocardial
r valvular disease. Cases selected (292 of 415 within the
riginal study) were those for whom all of the required
ariables were available for analysis. Originally, all 415 ANZ
eart failure subjects were sampled pre-randomization, and
NP was assayed in all (8). Residual plasma sample number
nd volumes permitted additional assay for NTproBNP (9) in
he 292 patients included in this report. As previously reported,
he 292 cases included in the current analyses did not differ
ignificantly in any measured variable from the remaining 123
NZ trial patients (9). Christchurch PMI patients (n  757)
ere admitted to the Christchurch Hospital coronary care unit
etween November 1994 and November 1999. Myocardial
nfarction was defined by typical ischemic symptoms, ischemic
hanges (including ST-segment elevation or depression or
ynamic T-wave changes, i.e., includes ST-segment elevation
nd non–ST-segment elevation infarcts) in two or more
lectrocardiogram leads and peak elevation of creatine kinase to
t least twice upper limit of normal. All were troponin-positive.
atients included in this report were all those surviving at least
our months after myocardial infarction, free of coronary events
r interventions for at least one month, and clinically stable.
lthough early post-infarction levels of BNP and NTproBNP
ave been related to function and prognosis in subgroups of
his cohort in previous publications (8,11,36), this is the first
eport relating late post-infarction (4 months) peptide levels
o concurrent left ventricular function and subsequent clinical
vents.
The two subgroups totaled 1,049 patients with the common
haracteristics of proven IHD and clinical stability.
easurements. Left ventricular ejection fraction was as-
essed by equilibrium-gated radionuclide ventriculography (co-
fficients of variation 5.3%) (37). Renal function was calcu-
ated as creatinine clearance according to the Cockroft-Gault
quation (38). Plasma NTproBNP and BNP concentrations
ere ascertained by previously well-validated and widely pub-
ished radioimmunoassays (26,27,39). Normal ranges (from
easurements in over 200 healthy men and women randomly
elected from the Christchurch electoral role) for BNP and
TproBNP (up to 97.5 percentile of normal subjects) were
40 and 425 pg/ml, respectively.
linical outcome. The composite end point employed in the
urrent report for analysis of the prognostic performance of
oth peptides was 12-month all-cause mortality and/or hospi-
al admission with heart failure.
tatistical analysis. Data are given as arithmetic mean values
SD. Peptide levels were loge transformed to normalize the
istributions, before all analyses. The normality of the log-
ransformed levels was confirmed by statistical tests of the
kewness and kurtosis of the resultant distributions. In no
nstance did these indicate significant departures from normal-
ty. Peptide levels were compared between genders using
u
c
v
C
t
t
m
o
a
(
u
H
a
K
m
i
C
i
P
o
d
h
R
T
c
t
r
D
I
(
b
t
a
a
i
3
w

0
t
0
m
d
t
o
i
c

e
p
L
r
f
4
s
p
p
r
2
t
o
2
B
F
rain n
termin
54 Richards et al. JACC Vol. 47, No. 1, 2006
B-Type Natriuretic Peptides in Stable IHD January 3, 2006:52–60npaired t tests. Pearson’s product moment correlation coeffi-
ients were used to test the strength of the associations of
ariables of interest with both BNP and NTproBNP values.
orrelations (standardized slopes, ) were compared using a z
est. The potential independent influences of age, renal func-
ion, gender, BMI, and LVEF on peptide levels were tested by
ultiple linear regression including all five variables with BNP
r NTproBNP as the dependent variable.
The ability of the peptides to detect LVEF 30%, 40%,
nd50% was assessed using receiver-operating characteristic
ROC) curves to provide optimal peptide values and areas
nder curves (AUC), which were compared by the method of
anley and McNeil (40). The rates of all-cause mortality
nd/or readmission with heart failure were calculated using
aplan-Meier survival curves and compared above and below
edian peptide level groups, using the log-rank test. The
ndependent predictive power of both peptides was tested by
ox proportional hazards multivariate analysis; the model
ncorporating age, recruitment from ANZ heart failure, or
MI cohorts; creatinine clearance; gender; LVEF; prescription
f angiotensin-converting enzyme inhibitors, beta-blockers,
iuretics; past history of documented myocardial infarction,
ypertension, or diabetes.
ESULTS
he study population included 1,049 patients with stable
oronary heart disease (with the expected gender distribu-
ion: 827 men and 222 [21%] women) encompassing a wide
ange of age, renal function, BMI, and LVEF (Table 1).
istribution among NYHA functional classes I, II, III, and
V was 63%, 30.4%, 6.2%, and 0.4%, respectively. In 588
56%) of the group, LVEF fell below 50%, in 330 (32%)
elow 40%, and in 141 (13%) below 30%. The proportions of
he group with previous myocardial infarction, hypertension,
nd diabetes were 97%, 39%, and 15%, respectively. Percent-
ges prescribed beta-blockers, angiotensin-converting enzyme
nhibitors, diuretics, and lipid-lowering agents were 69%, 59%,
5%, and 39%, respectively.
Plasma BNP and NTproBNP levels were higher in
omen than in men (80  73 pg/ml vs. 66  59 pg/ml; p
0.007, and 989  1,066 pg/ml vs. 778  795 pg/ml; p 
.005, respectively) with the ratio of mean levels in men to
hat in women being similar for both peptides (0.84 and
.78, respectively). Analyses were conducted separately for
Table 1. Age, LVEF, Renal Function, and B-
Stable Ischemic Heart Disease
Age
(yrs)
BMI
(kg/m2)
LVEF
(%)
Mean 63.4 26.7 46
SD 10.0 4.1 14
Min 25.8 16.5 10
Max 87.6 45.4 95
BMI  body mass index (weight(kg)/height[m]2); BNP  b
Max  maximum; Min  minimum; NTproBNP  aminoen and women and indicated no significant intergender
a
pifferences in the strength or slope of relationships between
he peptides and age, creatinine clearance, ejection fraction,
r BMI. Therefore, data from both genders was combined
n subsequent analyses and in Figures 1 to 4.
The close relationship between concurrent plasma con-
entrations of BNP and NTproBNP (r  0.9, n  1,049, p
0.001) is depicted in Figure 1; NTproBNP showed the
xpected higher numerical values at approximately 10-fold
lasma BNP values at all levels of LVEF (Fig. 2).
The significant inverse relationships of each peptide with
VEF are shown in Figure 2. The significant and compa-
able relationships of both peptides with age and with renal
unction are illustrated in Figure 3 and with BMI in Figure
. In none of these analyses (Figs. 2 through 4) did the
trength of correlations differ significantly between the two
eptide markers (p  0.05).
Multiple linear regression indicated LVEF was the most
owerful independent predictor of both peptides followed in
ank order by age, renal function, gender, and BMI (Table
). The R2 values for multiple linear regressions indicate
hat collectively these predictors explained approximately
ne-half the transformed variation in both peptides (Table
). Unadjusted data indicated 30% and 37% increments in
NP and NTproBNP, respectively, with each 10% decline
igure 1. Plasma brain natriuretic peptide (BNP) plotted against plasma
Natriuretic Peptides in 1,049 Patients With
tinine Clearance
(ml/min)
BNP
(pg/ml)
NTproBNP
(pg/ml)
80.6 69 820
32.9 69 863
16 7 25
270 887 9,523
atriuretic peptide; LVEF  left ventricular ejection fraction;
al pro-brain natriuretic peptide.Type
Creamino terminal pro-brain natriuretic peptide (NTproBNP) in 1,049
atients with stable ischemic heart disease.
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January 3, 2006:52–60 B-Type Natriuretic Peptides in Stable IHDn LVEF, 40% and 60% increases with each 10-year
ncrease in age, and 80% and 120% increments for each
alving of renal function (serial 30 ml/min decrements in
reatinine clearance from 150 ml/min down to 120, 90, 60,
nd 30 ml/min were associated with serial increments in
NP of 21%, 29%, 45%, and 86% and in NTproBNP of
2%, 38%, 60%, and 123%, respectively). Brain natriuretic
eptide and NTproBNP fell 15% and 22%, respectively,
ith each 5-U increment in BMI. When appropriately
djusted (for concurrent change in the other four variables),
10% decrement in LVEF corresponded to 21% and 24%
ncreases in BNP and NTproBNP, respectively, a 10-year
ncrement in age to 18% and 30% increments, and serial 30
l/min decrements in creatinine clearance from 150 ml/min
own to 30 ml/min corresponded to increments in BNP of
%, 22%, 44%, and 89% and in NTproBNP of 9%, 24%,
6%, and 95%. Each 5-U increment in BMI was associated
ith adjusted 3% and 9% decreases in BNP and NT-
roBNP, respectively.
Test performance of both peptides was conducted in the
otal study group and separately in the 649 asymptomatic
atients (NYHA functional class I). Compared with symp-
omatic patients, NYHA functional class I patients averaged
.5 years younger (62.4  10.4 years vs. 65.1  9.1 years, p
0.001), were less likely to have a previous history of
ypertension (37% vs. 43%, p  0.047) or diabetes (13% vs.
8%, p  0.015), had better creatinine clearance (86  33
l/min vs. 72  32 ml/min, p  0.001), better LVEF (49
13% vs. 41  13%, p  0.001), and had a lower
roportion of women (17% vs. 28%, p  0.001).
Receiver-operator characteristic curves indicated both
eptides had similar ability to detect LVEF below thresh-
lds of 30%, 40%, and 50% in the total study group (Fig. 5)
nd in the asymptomatic (NYHA functional class I; n 
49) subgroup (Fig. 6). For both peptides, the AUC was
ignificantly less for detection of LVEF below 50% (AUCs
.75 and 0.73 for BNP and NTproBNP, respectively) than
elow 30% (AUCs 0.83 and 0.80, respectively; p  0.01 for
igure 4. Body mass index plotted against brain natriuretic peptide (BNP)
closed symbols) and amino terminal pro-brain natriuretic peptide (NT-igure 2. Left ventricular ejection fraction (LVEF) plotted against brain
atriuretic peptide (BNP) (closed symbols) and amino terminal pro-brainigure 3. Age (top) and creatinine clearance (CrCl) (bottom) plotted
gainst brain natriuretic peptide (BNP) (closed symbols) and aminoroBNP) (open symbols) in 1,049 patients with stable ischemic heart
isease.
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B-Type Natriuretic Peptides in Stable IHD January 3, 2006:52–60oth comparisons within the total study group). Sensitivity,
pecificity, positive predictive value, negative predictive
alue, and overall accuracy for the optimal levels of each
eptide lying on each of the ROC curves are shown in Table
. Values for these test performance characteristics were
imilar for both peptides in the total group and asymptom-
tic subgroup and at all three LVEF thresholds. At an
VEF threshold of 30%, consistently high negative predic-
ive values (94% or higher) were observed for optimal levels
f both peptides in both subgroups; ROC curves and test
erformance characteristics were also significant and similar
or men and women analyzed separately (data not shown).
Seventy-nine patients (7.5%) died and/or were readmit-
ed to hospital for heart failure. Brain natriuretic peptide
nd NTproBNP were higher (double) in those incurring,
ompared with those spared, these adverse outcomes (129
4 pg/ml vs. 65  2 pg/ml and 1,591  156 pg/ml vs. 757
25 pg/ml for BNP and NTproBNP, respectively; p 
.001 for both). Event-free survival curves for the two
eptide markers were closely overlapped with greater risk of
dverse outcomes in those with peptide levels above com-
ared with below the median (Fig. 7, cumulative event rates
f 12% vs. 3% for both peptides). Unadjusted risk ratios
95% confidence intervals) were 4.07 (2.38 to 6.94) and 4.15
2.40 to 7.19) for BNP and NTproBNP, respectively (p 
.001 for both). On Cox proportional hazards multivariate
nalysis, both BNP and NTproBNP remained indepen-
ently predictive with adjusted risk ratios of 1.89 (1.02 to
.52) and 2.08 (1.12 to 3.89), respectively (p  0.05 for
oth).
ISCUSSION
n patients with stable IHD, BNP and NTproBNP were
losely correlated and exhibited parallel changes across a
road range of age, renal function, and LVEF. The two
arkers performed similarly in the detection of LVEF
educed below 30%, 40%, or 50%, in symptomatic and
symptomatic patients, and were indistinguishable in their
bility to predict 12-month all-cause mortality and/or read-
ission with heart failure.
Existing studies in cardiac clinical cohorts have examined
ituations in which B-type peptides are generally higher
han in stable IHD and rapidly changing in an evolving
esponse to recent clinical instability (1–17). This report
rovides new information on the test performance of BNP
Table 2. Multiple Linear Regression Assessing
as Independent Predictors of Plasma BNP and
Age
(yrs)
C
BNP t 7.50
(R2  0.45) p 0.0001
NTproBNP t 9.03
(R2  0.43) p 0.0001
Abbreviations as in Table 1.nd NTproBNP across a broad spectrum of stable IHD. Ihe group studied is representative of the ambulant IHD
opulation, which generates a large part of cardiac practice.
e confirm previously described relationships of the two
eptides to one another and to cardiac function and prog-
osis (1,4,7,11,36). In this stable group, mean BNP and
TproBNP levels were raised to approximately twice the
pper limits of normal, comparable to levels in chronic
table heart failure, and lower than observed in acute heart
ailure or in the early PMI period (1–5,9–11,36).
By ROC analysis, both peptides had good power to
etect LVEF 30% with AUC of 0.80 to 0.85 for both
eptides in the group overall, with similar performance in
he asymptomatic subgroup (Fig. 2). As noted previously in
any settings, the negative predictive value of both peptides
n ruling out severe systolic ventricular dysfunction (LVEF
30%) was consistently high in these stable patients (94%
r higher) whether or not symptoms were present.
The ability of both peptides to predict 12-month all-
ause mortality and/or admission with heart failure was
lear-cut and comparable to the prognostic strength exhib-
ted by both peptides in both acute coronary or established
eart failure cohorts (6–8,10–13,15).
Our results do not support previous claims that the test
erformance of one or other of the two markers is more
nfluenced by gender, age, or renal function, or that one of
he two markers is superior in detecting milder degrees of
eft ventricular dysfunction in asymptomatic patients (27–
2). Age and renal function both independently influenced
oth BNP and NTproBNP levels to an important degree
ith absolute and proportional changes in NTproBNP
enerally more pronounced than concurrent shifts in BNP,
onsistent with an analyte with mean levels 10-fold higher
han the comparator peptide and in which slower metabolic
learance will ensure greater increments in plasma levels for
ny disturbance generating increased secretion. However,
ny differences in absolute or proportional shifts of BNP
ompared to NTproBNP did not result in differences in test
erformance. The close match of ROC curves for selected
VEF threshold values (Fig. 2) and overlapping event-free
urvival curves (Fig. 3) confirm these background factors
nfluence the test performance of one peptide no more than
he other.
The effects of gender, age, and renal function suggest the
se of these markers for follow-up of ventricular function
nd for risk stratification in individual patients with stable
, Renal Function, Gender, BMI, and LVEF
proBNP
ine Clearance
ml/min) Gender
BMI
(kg/m2)
LVEF
(%)
6.43 3.08 1.22 17.88
0.0001 0.003 0.223 0.0001
5.12 3.34 3.03 15.90
0.0001 0.002 0.003 0.0001Age
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January 3, 2006:52–60 B-Type Natriuretic Peptides in Stable IHDatients, an additional decade of life, a 10% decrement in
VEF (e.g., a fall from 40% to 30%), and a 30 ml/min fall
n creatinine clearance (i.e., from 120 to 90 ml/min) are
ssociated with similar increments (20% to 30%) in plasma
NP and NTproBNP. A doubling in mean peptide levels is
ssociated with an approximate doubling in 12-month risk
adjusted) of death or decompensated heart failure. Brain
atriuretic peptide and NTproBNP levels in those present-
igure 5. Receiver-operating characteristic curves for detection of left
entricular ejection fraction (LVEF) 30% (top), 40% (middle), or 50%
bottom) by brain natriuretic peptide (BNP) (solid lines) and amino
erminal pro-brain natriuretic peptide (NTproBNP) (dotted lines) in
,049 patients with stable ischemic heart disease. Curves do not signifi-
antly differ for any level of LVEF. AUC  area under the curve.ng with dyspnea due to heart failure are, respectively, 6- cnd 12-fold those observed in patients with a non-cardiac
ause (3,4). Hence, the “signal-to-noise” ratio in the latter
pplication is far more robust than in the assessment of
unction and prognosis in stable IHD. Despite these reser-
ations, the current data still indicate that both peptides
etain high negative predictive value for ruling out severe
eduction in LVEF even without adjustment for potential
igure 6. Receiver-operating characteristic curves for detection of left
entricular ejection fraction (LVEF) 30% (top), 40% (middle), and 50%
bottom) by brain natriuretic peptide (BNP) (solid lines) or amino
erminal pro-brain natriuretic peptide (NTproBNP) (dotted lines) in
,049 patients with asymptomatic stable ischemic heart disease. AUC 
rea under the curve.onfounders.
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B-Type Natriuretic Peptides in Stable IHD January 3, 2006:52–60The current analyses apply to patients with stable IHD.
n this group, a broad spectrum of age, renal function, and
ardiac function is represented. The population studied in
he current study is representative of much of the common-
lace workload of cardiology throughout the Western
orld.
It remains possible subtle differences between BNP and
TproBNP in test performance may be observed when
omparing their ability to distinguish truly normal subjects
rom those with asymptomatic or early heart disease, or that
igure 7. Kaplan-Meier event-free survival curves for death or heart failure
dmission for those with brain natriuretic peptide (BNP) (solid lines) and
mino terminal pro-brain natriuretic peptide (NTproBNP) (dotted lines)
bove (lower two lines) or below (upper two lines) the median level for the
able 3. Peptide Test Performance in Detection of Selected LVE
Optimal Value
(pg/ml)
NP
All (n  1,049)
LVEF
30% 78
40% 54
50% 47
YHA functional class I (n  649)
LVEF
30% 71
40% 50
50% 47
TproBNP
All (n  1,049)
LVEF
30% 922
40% 588
50% 562
YHA functional class I (n  649)
LVEF
30% 994
40% 545
50% 512
PV  negative predictive value; NYHA  New York Heart Association; PPV  posp
roup. For both peptides, the separation of survival curves was highly
ignificant (p  0.001). CHF  congestive heart failure.n other forms of heart disease the two may perform
omewhat differently. Differences in peptide plasma half-life
ay enable BNP to more rapidly reflect evolving changes in
emodynamic status occurring over short periods of time as
n the setting of introduction of intensive parenteral therapy
n decompensated heart failure; NTproBNP may prove a
ore reliable indicator of cardiac status when BNP itself is
dministered as therapy or in the presence of other treat-
ents that modify plasma clearance of BNP. However,
hese considerations in no way refute the evident inter-
hangeability of these two markers in the assessment of
ardiac function and prognosis in stable IHD.
The analyses were conducted with radioimmunoassays,
alidated in the course of multiple publications (1,4,8,9,11,
9,26,27,39), which correlate closely with currently available
idely used commercial assays for both NTproBNP and
NP (r 0.91 for relationships of both assays to both
IOSITE point of care BNP assays [BIOSITE Inc., San
iego, California] and the Roche Diagnostics NTproBNP
ssay [Roche Diagnostics, Indianapolis, Indiana]). Both
ssays exhibit near-identical ROC curves and test perfor-
ance characteristics to the two commercially available
ssays when used to diagnose heart failure in dyspneic
atients (4).
Across the broad spectrum of stable IHD plasma BNP
nd NTproBNP are powerful indicators of ventricular
unction and independent predictors of clinical outcome.
hey are similarly and independently influenced by gender,
ge, and renal function and have indistinguishable perfor-
ance in detection of left ventricular dysfunction and as
hresholds in Patients With Stable Ischemic Heart Disease
s
)
Spec
(%)
PPV
(%)
NPV
(%)
Accuracy
(%)
77 33 95 76
65 50 86 69
64 72 65 69
79 25 97 78
69 42 92 71
71 66 71 69
79 34 94 77
66 49 85 68
73 75 61 67
86 31 97 84
69 40 90 69
73 66 69 68
redictive value; Sens  sensitivity; Spec  specificity; other abbreviations as in Table 1.F T
Sen
(%
75
78
73
75
79
66
70
71
63
68
72
62rognostic markers.
A
S
A
R
D
n
m
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
59JACC Vol. 47, No. 1, 2006 Richards et al.
January 3, 2006:52–60 B-Type Natriuretic Peptides in Stable IHDcknowledgments
tatistical and graphical assistance was provided by Alisa
lspach. Barbara Griffin provided secretarial assistance.
eprint requests and correspondence: Dr. A. Mark Richards,
epartment of Medicine, Christchurch Hospital, Riccarton Ave-
ue, PO Box 4345, Christchurch, New Zealand. E-mail:
ark.richards@cdhb.govt.nz.
EFERENCES
1. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic
peptide in assessment of acute dyspnoea. Lancet 1994;343:440–4.
2. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic
peptides in assessment of patients with possible new heart failure in
primary care. Lancet 1997;350:1349–53.
3. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement
of B-type natriuretic peptide in the emergency diagnosis of heart
failure. N Engl J Med 2002;347:161–7.
4. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls
MG, Richards AM. Brain natriuretic peptide and N-terminal brain
natriuretic peptide in the diagnosis of heart failure in patients with
acute shortness of breath. J Am Coll Cardiol 2003;42:728–35.
5. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic
peptide in the evaluation and management of acute dyspnea. N Engl
J Med 2004;350:647–54.
6. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation
of endogenous cardiac natriuretic peptide system in chronic heart
failure: prognostic role of plasma brain natriuretic peptide concentra-
tion in patients with chronic symptomatic left ventricular dysfunction.
Circulation 1997;96:509–16.
7. Omland T, Aakvaag A, Bonarjee VVS, et al. Plasma brain natriuretic
peptide as an indicator of left ventricular systolic function and
long-term survival after acute myocardial infarction. Comparison with
plasma atrial natriuretic peptide and N-terminal proatrial natriuretic
peptide. Circulation 1996;93:1963–9.
8. Richards AM, Doughty R, Nicholls MG, et al. Neurohumoral
prediction of benefit from carvedilol in ischemic left ventricular
dysfunction. Circulation 1999;99:786–92.
9. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal
pro-brain natriuretic peptide and adrenomedullin. Prognostic utility
and prediction of benefit from carvedilol in chronic ischemic left
ventricular dysfunction. J Am Coll Cardiol 2001;37:1781–7.
0. Anand IS, Fisher LD, Chiang Y-T, et al. Changes in brain natriuretic
peptide and norepinephrine over time and mortality and morbidity in
the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:
1278–83.
1. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal
pro-brain natriuretic peptide and adrenomedullin: new neurohormonal
predictors of left ventricular function and prognosis after myocardial
infarction. Circulation 1998;97:1921–9.
2. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of
B-type natriuretic peptide in patients with acute coronary syndromes.
N Engl J Med 2001;345:1014–21.
3. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain
natriuretic peptide and other risk markers for the separate prediction of
mortality and subsequent myocardial infarction in patients with
unstable coronary artery disease. A Global Utilization of Strategies To
Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:
275–81.
4. Heeschen C, Hamm CW, Mitrovic V, Lantelme N-H, White HD,
for the Platelet Receptor Inhibition in Ischemic Syndrome Manage-
ment (PRISM) Investigators. N-terminal pro-B-type natriuretic pep-
tide levels for dynamic risk stratification of patients with acute
coronary syndrome. Circulation 2004;110:3206–12.
5. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain
natriuretic peptide on admission for early risk stratification of patients
with chest pain and no ST-segment elevation. J Am Coll Cardiol
2002;40:437–45.6. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type
peptide predicts treatment outcomes in patients admitted for decom-pensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:
386–91.
7. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natri-
uretic peptide assay for identifying patients at high risk of readmission
after decompensated heart failure. J Am Coll Cardiol 2004;43:635–41.
8. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator
therapy in chronic heart failure according to plasma brain natriuretic
peptide concentration: randomized comparison of the hemodynamic
and neuroendocrine effects of tailored versus empirical therapy. Am
Heart J 1999;138:1126–32.
9. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls
MG, Richards AM. Treatment of heart failure guided by plasma
aminoterminal brain natriuretic peptide (N-BNP) concentrations.
Lancet 2000;355:1126–30.
0. Wallen T, Landahl S, Hedner T, Nakao K, Saito Y. Brain natriuretic
peptide predicts mortality in the elderly. Heart 1997;77:264–7.
1. Johnston N, Jernberg T, Lindahl B, et al. Biochemical indicators of
cardiac and renal function in a healthy elderly population. Clin
Biochem 2004;37:210–6.
2. Hobbs FDR, Davis RC, Roalfe AK, et al. Reliability of N-terminal
pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort
study in representative and high risk community populations. BMJ
2002;324:1498–500.
3. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides
for community screening for left ventricular hypertrophy and systolic
dysfunction. The Framingham Heart Study. JAMA 2002;288:1252–9.
4. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels
and the risk of cardiovascular events and death. N Engl J Med
2004;350:655–63.
5. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR,
Burnett JC, Jr. Plasma brain natriuretic peptide to detect preclinical
ventricular systolic or diastolic dysfunction. A community-based study.
Circulation 2004;109:3176–81.
6. Hunt PJ, Yandle TG, Nicholls MG, Richards AM, Espiner EA. The
amino-terminal portion of pro-brain natriuretic peptide (pro-BNP)
circulates in human plasma. Biochem Biophys Res Commun 1995;
214:1175–83.
7. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN,
Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic
peptide (NT-PROBNP): a new marker of cardiac impairment. Clin
Endocrinol (Oxf) 1997;47:287–96.
8. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Head-to-head
comparison of the diagnostic utility of BNP and NT-proBNP in
symptomatic and asymptomatic structural heart disease. Clin Chim
Acta 2004;341:41–8.
9. Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP
and BNP measurements in cardiac care: a more discerning marker for
the detection and evaluation of heart failure. Eur J Heart Fail
2004;6:295–300.
0. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of
NT-proBNP in routine testing and comparison to BNP. Eur J Heart
Fail 2004;6:289–93.
1. Hammerer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschen-
dorf B, Mair J. Head-to-head comparison of N-terminal pro-brain
natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial
natriuretic peptide in diagnosing left ventricular dysfunction. Clin
Chim Acta 2001;310:193–7.
2. McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides:
a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003;
4:72–80.
3. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide
and renal function in the diagnosis of heart failure: an analysis from the
Breathing Not Properly Multinational study. Am J Kidney Dis
2003;41:571–9.
4. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR,
Burnett JC, Jr. Plasma brain natriuretic peptide concentration: impact
of age and gender. J Am Coll Cardiol 2002;40:976–82.
5. Australia/New Zealand Heart Failure Research Collaborative Group.
Randomised, placebo-controlled trial of carvedilol in patients with
congestive heart failure due to ischaemic heart disease. Lancet 1997;
349:375–80.
6. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic
peptides and ejection fraction for prognosis after myocardial infarction.
Circulation 2003;107:2786–92.
33
3
4
A
F
N
60 Richards et al. JACC Vol. 47, No. 1, 2006
B-Type Natriuretic Peptides in Stable IHD January 3, 2006:52–607. Maddox DE, Holman BL, Wynne J, et al. Ejection fraction image: a
non-invasive index of regional left ventricular wall motion. Am J
Cardiol 1978;41:1230–42.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from
serum creatinine. Nephron 1976;16:31–41.
9. Yandle TG, Richards AM, Gilbert A, Fisher S, Holmes S, Espiner
EA. Assay of brain natriuretic peptide (BNP) in human plasma:
evidence for high molecular weight BNP as a major plasma component
in heart failure. J Clin Endocrinol Metab 1993;76:832–8. p0. Hanley JA, McNeil BJ. A method of comparing the areas under
receiver operating characteristic curves derived from the same cases.
Radiology 1983;148:839–43.
PPENDIX
or a list of investigators who participated in the Australia-
ew Zealand Heart Failure Research Collaborative Group,lease see the online version of this article.
